Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 14Phase NA 9Phase 1/2 4Phase 3 3Phase 2/3 3

Status

Completed 12Active not recruiting 5Unknown 4Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 48Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 41Stomach Neoplasms 35Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Neoplasm Metastasis 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Oxaliplatin 2Nivolumab 2Leucovorin 2Fluorouracil 2zolbetuximab 1pertuzumab 1dehydroftorafur 1Trastuzumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Adenocarcinoma Of Esophagus × Clear all
NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05677490 2026-05-08

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Alliance for Clinical Trials in Oncology

Phase 3 Recruiting
382 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT05188313 2022-06-24

TRAP-2

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 3 Recruiting
376 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡